


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In re Patent Application of: Nam Joong KIM, et al.

Serial No.: 09/926,590

Group Art Unit: 1615

Filed: November 21, 2001

Examiner: Di Nola Baron, Liliana

For: SOMATOTROPIN COMPOSITION WITH IMPROVED SYRINGEABILITY

* * * * *

TRANSMITTALHonorable Commissioner for Patents
Washington, D.C. 20231

April 29, 2003

Sir:

Transmitted herewith is an Amendment.

The fee has been calculated as shown below:

Claims Remaining After Amendment	Highest Number Previously Paid For	Present Extra	Small Entity Fee	Other Than A Small Entity Fee
Total 13 -	20 =	0	x 09 = \$	x 18 = \$
Indep. 01 -	03=	0	x 42 = \$	x 84 = \$
	First Presentation of Multiple Dependent Claims	+140 = \$	+ 280 = \$	
	Total Additional Fee	\$		\$

 A check in the amount of \$_____ is attached for:

If a Petition for Extension of Time is necessary and the Petition and/or the check is not enclosed, this will act as the Petition and applicant herewith petitions the Commissioner to extend the time for response and charge any fees necessary under 37 CFR 1.17 (a)(1)-(5) to Deposit Account No. 06-1358. The Commissioner is also authorized to charge payment of any other additional fees associated with this communication or credit any overpayment to Deposit Account No. 06-1358. A duplicate copy of this sheet is attached.

Respectfully submitted,

JACOBSON HOLMAN, PLLC

By: 
Yoon S. Ham
Reg. No. 45,307

The Jenifer Building
400 Seventh Street, N.W.
Washington, D.C. 20004-2201
Telephone: (202) 638-6666
Atty. Docket: P67297US0
YSH:dj

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application:

Nam Joong KIM, et al.

Serial No.: 09/926,590

Filed: November 21, 2001

For: SOMATOTROPIN COMPOSITION WITH
IMPROVED SYRINGEABILITY



MAY 01 2003

TECH CENTER 1600/2900

Group Art Unit: 1615

Examiner: L. Di Nola Baron

J. Tuck
S/B
3/1
3/4/03

Commissioner of Patents
Washington, D.C. 20231

April 29, 2003

Sir:

Responsive to the Office Action (Paper No. 7) of January 30, 2003, kindly amend the claims of the above-identified application as follows:

In the Claims:

Cancel claims 1 to 14 without prejudice or disclaimer, and insert the following claims in lieu thereof:

--15. (Replacing claim 1) A composition which consists of somatotropin, a lipid-soluble vitamin, and a pharmaceutically acceptable lubricant.

16. (Replacing claim 2) The composition according to claim 15, wherein the somatotropin is produced by recombinant DNA technology.

17. (Replacing claim 3) The composition according to claim 15, wherein the somatotropin is present in an amount of from 10 to 50% by weight, based on the total weight of the composition.

18. (Replacing claim 4) The composition according to claim 15, wherein the lipid-soluble